Etoricoxib is a type of nonsteroidal anti-inflammatory drug (NSAID) known as a COX-2 inhibitor. Thiocolchicoside is an anti-inflammatory and analgesic muscle relaxant. Combination of Etoricoxib and Thiocolchicoside is used in the management of pain of muscle spasm. Simultaneous estimation of Etoricoxib and Thiocolchicoside in combined pharmaceutical dosage forms, a cost-effective RP-HPLC method using a PDA detector at 245 nm wavelength has been developed. The method was validated in accordance with ICH guidelines for Etoricoxib and Thiocolchicoside respectively, over concentration ranges of 20–160 ppm and 1–10 ppm. Analyzer column temperature of 25°C +/- 0.5°C was used with Puritas Eximius C18, 250 X 4.6 mm, five microns. Mobile phase used was acetonitrile and 0.1% acetic acid in water were mixed in a 70:30 volume-to-volume composition and flow rate of 1.0 mL/min was used. Retention times of 4.2 and 2.1 min were obtained for Etoricoxib and Thiocolchicoside respectively. Etoricoxib and Thiocolchicoside have percentage recoveries of 98.28% and 102.1%, respectively. Every time, the relative standard deviations are under 2%.